Share on StockTwits

Pernix Therapeutics Holdings (NYSE:PTX) posted its quarterly earnings results on Monday. The company reported ($0.16) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.05) by $0.11, Analyst Ratings Network.com reports. The company had revenue of $17.40 million for the quarter, compared to the consensus estimate of $26.20 million. During the same quarter last year, the company posted ($0.16) earnings per share.

Pernix Therapeutics Holdings (NYSE:PTX) opened at 6.38 on Monday. Pernix Therapeutics Holdings has a 1-year low of $1.68 and a 1-year high of $9.56. The stock has a 50-day moving average of $8.25 and a 200-day moving average of $5.61. The company’s market cap is $241.0 million.

A number of research firms have recently commented on PTX. Analysts at Citigroup Inc. upgraded shares of Pernix Therapeutics Holdings from a “hold” rating to a “buy” rating in a research note on Tuesday, May 27th. On a related note, analysts at Aegis upgraded shares of Pernix Therapeutics Holdings from a “hold” rating to a “buy” rating in a research note on Tuesday, May 27th. Finally, analysts at Needham & Company LLC upgraded shares of Pernix Therapeutics Holdings from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 15th. They now have a $10.00 price target on the stock, up previously from $6.30. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Pernix Therapeutics Holdings currently has a consensus rating of “Buy” and an average price target of $6.00.

Pernix Therapeutics Holdings, Inc (NYSE:PTX) is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products for pediatric and adult indications in a range of therapeutic areas.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.